Ei.Ventures
SeedRaised Since FeaturedNatural psychedelic medicine
Hawaii-based psychedelic startup developing psilocybin therapies and nutraceuticals for mental health.
About
Ei.Ventures (Emotional Intelligence Ventures) is pioneering accessible, plant-derived psychedelic therapies to address the global mental health crisis. Founded in 2019 by serial entrepreneur David Nikzad, the company takes a dual-track approach: pursuing FDA-regulated psilocybin drug candidates while simultaneously building a consumer nutraceutical line. Their flagship innovation is the Psilly Patch, a patent-pending transdermal psilocybin delivery system, alongside micro-dosing tablets and a proprietary Botanical Psychedelic API — a comprehensive data platform cataloging psychedelic compounds. With 21 provisional patents filed, SEC qualification to raise $50M in public equity, and over $20M raised from 10,500+ shareholders, Ei.Ventures has built one of the most ambitious vertically integrated psychedelic medicine platforms. In 2022, the company entered a definitive agreement for a $382M merger with Mycotopia Therapies, aiming to uplist to NASDAQ under PSLY.com.
DailyDropout Take
Ei.Ventures caught our attention with their dual-track approach to psychedelic medicine — building both consumer wellness products and an FDA pharmaceutical pipeline simultaneously. With 21 provisional patents, SEC-qualified public fundraising, and a proprietary transdermal psilocybin delivery system, they're positioning to make psychedelic therapies accessible to the 322 million people suffering from depression worldwide.
Discovery signal: Unique vertically integrated approach spanning nutraceuticals to FDA drug candidates, SEC-qualified public offering, 21 provisional patents in a nascent but rapidly growing psychedelic medicine market.
What Makes Them Unique
Ei.Ventures combines a consumer-facing nutraceutical mushroom line with an FDA pharmaceutical pipeline and a proprietary transdermal psilocybin delivery system (Psilly Patch), creating a vertically integrated platform spanning wellness products to clinical-grade psychedelic therapies.
21
Provisional Patents
$50M
SEC-Qualified Raise
10,500+
Shareholders
$382M
Merger Valuation
Target Markets
Founders
David Nikzad
Co-Founder & CEO
Serial entrepreneur and venture capitalist based in Hawaii. Founded Ei.Ventures in 2019 to pursue accessible psychedelic medicine.
Jason Hobson
Co-Founder
Long-time collaborator of David Nikzad with over 20 years of partnership. Co-founded Ei.Ventures to develop psychedelic therapies.
Linda Strause
President
Serves as President of Ei.Ventures, overseeing operations and strategic direction of the company's psychedelic medicine programs.
Funding History
Lead: Public Offering